Yuyu Pharma, a global pharmaceutical company based in Korea, selected Robert Wonsang Yu as president and CEO.
PTC Therapeutics Inc. appointed Matthew Klein, M.D., as chief development officer and Eric Pauwels as chief business officer.
The board of directors of BioSpecifics Technologies Corp. appointed Joseph Truitt as interim CEO. He will also serve on the company’s board of directors. Truitt succeeds J. Kevin Buchi, who served as CEO since October 2019, and has departed the company. “We are delighted to have Joe on board and believe he will play a […]
Tatsuya Kaihara was tapped as corporate officer and head of North America business of Santen Pharmaceutical Co. Ltd.
Q BioMed Inc., a commercial-stage biotech company, appointed Geoff Fatzinger as the global head of regulatory affairs.
EVERSANA a leading independent provider of global commercial services to the life sciences industry, appointed Ed Cox to executive VP, strategic alliances and global head of the company’s new digital medicine practice area.
Seneca Biopharma Inc., a clinical-stage biopharmaceutical company, appointed Matthew W. Kalnik, Ph.D. as president and chief operating officer and Dane R. Saglio as chief financial officer. Seneca also promoted Thomas Hazel, Ph.D., to the newly created position of senior VP of research and development.
Antengene Corp. appointed Thomas Karalis as head of Asia Pacific Regions.
“Put the patient first.” It’s every pharma marketer’s favorite buzz-phrase in 2020. And why not? Patients are our real customers; they use and (hopefully) benefit from our products, and their wants and needs drive the success or failure of everything we do.
With 270 million Americans currently under a “stay at home” directive, only activities deemed “essential” are happening in person. In healthcare, which relies significantly on personal connections – between patients and HCPs, HCPs and pharma reps, and even marketers and their teams – there have been dramatic shifts in the way we all work and operate over the last couple of weeks.